Aquestive Therapeutics, Inc. (AQST) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Aquestive Therapeutics, Inc.'s filing signal turned negative.

Aquestive Therapeutics is a pharmaceutical company focused on developing and commercializing innovative drug delivery technologies, primarily its proprietary PharmFilm(R) oral film platform. The company is advancing AnaphylmTM, a sublingual film for anaphylaxis treatment, and has a pipeline of epinephrine prodrug candidates under its AdrenaVerseTM platform. Aquestive also manufactures and supplies four licensed commercialized products, including Suboxone(R), and has a history of developing CNS-focused products like Libervant(R) for epilepsy. Its manufacturing facilities are located in Portage, Indiana, with headquarters in Warren, New Jersey, and its products have received inspections from major regulatory bodies like the FDA.

Revenue is generated from the manufacture and supply of licensed products, license and royalty fees from intellectual property, co-development and research fees, and sales of proprietary products.